Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of concomitant versus staggered RotaTeq and IPV administration in healthy Chinese infants
2020-003329-49Phase 3
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rotavirus vaccine, live, oral, pentavalent and inactivated poliovirus vaccine in rotaviral diarrhea and poliomyelitis (2 arms), sponsored by Merck & Co. Primary endpoint: Neutralizing antibody seroconversion to poliovirus types 1, 2, and 3.
02
Drugs
rotavirus vaccine, live, oral, pentavalentinactivated poliovirus vaccine
03
Conditions
rotaviral diarrheapoliomyelitis
Beyond the preview
Go deeper on 2020-003329-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003329-49.